MYNZ Mainz Biomed B.V.
USHealthcareAs of 2026-05-22 12:35
Why MYNZ matters now
Mainz Biomed B.V. (MYNZ) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.59 with +0.84% on the session and $14.7M in market capitalization; recent performance reads 1-month +42.46% and YTD +220.54%.
The latest financial table shown here is Q4 2025, with revenue of $250.4K, net income of $-7.9M, and EPS of $-0.43. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -25.1%.
Additional event context on this page matters because analyst consensus is Hold with a median target of $—; recent insider activity includes Ben-Tzvi Avraham filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
4.53
P/S
76.82
EV/EBITDA
-2.37
DCF Value
$-1.68
FCF Yield
-25.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-2723.5%
Net Margin
-2937.8%
ROE
-244.2%
ROA
-109.1%
ROIC
-165.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $250.4K | $-7.9M | $-0.43 |
| FY 2025 | $537.1K | $-16.2M | $-2.70 |
| Q2 2025 | $286.7K | $-8.3M | $-2.65 |
| Q4 2024 | $373.2K | $-10.6M | $-7.71 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Company Info
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
DE
Exchange
—
Beta
0.32
Mainz Biomed B.V. is a German company specializing in molecular genetics for the development of cancer diagnostics. The firm engineers both in-vitro diagnostic (IVD) tools and assays designed exclusively for research, primarily catering to clinical applications within human genetics. Among its key offerings is ColoAlert, a screening test for detecting colorectal cancer. Additionally, they are developing PancAlert, a promising product candidate intended for pancreatic cancer screening. Beyond cancer, Mainz Biomed also provides GenoStrip, a molecular genetic solution for identifying pathogens in various environments. Established in 2008, the company maintains its headquarters in Mainz, Germany.